Render Target: STATIC
Render Timestamp: 2025-03-14T10:24:42.545Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:17:11.095
Product last modified at: 2025-02-04T12:45:14.466Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Myoferlin (E9Z4X) Rabbit mAb #99293

Filter:
  • WB
  • IF

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 250
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Immunocytochemistry) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Myoferlin (E9Z4X) Rabbit mAb recognizes endogenous levels of total myoferlin protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human myoferlin protein.

    Background

    Myoferlin (MYOF) is a type II transmembrane protein of the ferlin family found mainly in muscle and endothelial cells (1,2). The protein has multiple C2 domains located at its N-terminal cytoplasmic region, which mediate lipid binding and protein-protein interactions (3). Myoferlin is localized to various membrane structures, including the plasma membrane and vesicle membranes, to promote vesicle trafficking (4,5), membrane fusion and repair (6), angiogenesis (7), and adipogenesis (8). High expression of myoferlin has been found in various cancer types and is associated with poor prognosis (3,9). Myoferlin contributes to cancer progression by promoting angiogenesis, vasculogenic mimicry, energy metabolism reprogramming, epithelial-mesenchymal transition, and exosome formation. Inhibition of myoferlin has been proposed as a potential therapeutic treatment for cancer (10-12).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.